Sweetch Overview
Sweetch ingeniously merges AI with behavioral science, empowering patients to better manage their chronic conditions. By harnessing data gleaned from patients' smartphones and connected devices, Sweetch crafts real-time, hyper-personalized recommendations that cater to the nuances of an individual's health journey. The solution have shown significant results – clinical outcomes, user satisfaction, and ROI. Sweetch's proprietary Just-in-Time-Adaptive-Intervention (JITAI) technology fine-tunes patient-user interactions by continuously analyzing ongoing patient context and past behavior patterns. Sweetch’s highly dynamic adaptation ensures that each patient's evolving needs are addressed in real time. Interaction with users is intricately tailored, accounting for factors like timing, location, tone of voice, and other personalized elements. The result is an unparalleled experience that drives up engagement and retention to deliver outsized improvements in clinical outcomes and business KPIs.
Cumulative Funding Raised Over Time ($)
$1.3MApr 2015
$4.8MApr 2016
$12.8MApr 2024
$12.8MAug 2024
$14.3MFeb 2019
$34.3MJul 2021
$44.8MMay 2020
$44.8MMay 2025
Latest News
growth-positive
Sweetch Strengthens Advisory Board with Appointment of Obesity Medicine Expert and Innovator, Dr. Fatima Cody Stanford
Dr. Fatima Cody Stanford, an obesity medicine physician-scientist, has joined Sweetch as an advisor. Sweetch is a digital therapeutics innovator and creator of a precision engagement platform for chronic conditions. Dr. Stanford will help Sweetch implement obesity management practices with her expertise. The prevalence of obesity and overweight is increasing worldwide, and Sweetch aims to decrease the health impact of obesity through its hyper-personalized engagement solutions. Dr. Stanfords addition to the advisory board is expected to improve patients lives globally.
Partners
growth-positive
Sweetch 2.0 Revolutionizes Patient Partnership in Managing Chronic Disease Management
Sweetch, a digital therapeutics innovator, has announced a platform update to help patients comply with their chronic condition management regimens. The platform combines AI and EI technology to provide hyper-personalized recommendations and engage patients in their health journey. The new version features a consumer-app style interface and allows patients to create and implement plans for participatory health. It also provides insight into how specific behaviors affect cardiometabolic health. Sweetch aims to improve adherence to treatment regimens and achieve better health outcomes. The company is being used by some of the worlds largest healthcare organizations.
Customers
growth-positive
Sweetch Enters Strategic Partnership with Grupo Fleury's Saúde iD to Tackle Brazil's Chronic Disease Prevalence Amidst COVID-19 Pandemic
Sweetch has announced a partnership with Grupo Fleury, one of Brazils leading healthcare providers. Fleury will implement Sweetch as part of its Saúde iD telemedicine services to improve healthcare outcomes for patients with chronic conditions. The partnership aims to reach millions of patients struggling to adhere to their prescribed health regimens and minimize healthcare costs. Sweetchs platform has been clinically proven to motivate long-lasting behavioral change and adherence. The initial deployment will focus on patients with obesity, pre-diabetes, and Type 2 diabetes, with plans to expand to other chronic health conditions. The integration of Sweetchs program in Fleurys divisions has already shown positive results, including increased physical activity and weight loss among users. Brazil has a high prevalence of chronic diseases, and Sweetch aims to address these underlying conditions to reduce the risk of COVID-19 complications. The partnership is part of Fleurys growth plan to build a Sweetch community of hundreds of thousands of users within three years.
Partners
growth-positive
Sweetch Secures $20 Million Series A to Accelerate Fully Automated Hyper-personalized Engagement Between Health Ecosystem Players and People with Chronic Conditions
Sweetch, a digital therapeutics innovator, has completed a $20 million Series A funding round. The funds will be used for global expansion and further development of their AI and emotional intelligence behavioral science technology. The funding round was led by Entrée Capital and joined by several other investors. Sweetchs platform is used for chronic disease management and has shown significant improvements in clinical outcomes. The company aims to provide a hyper-personalized solution to increase patient adherence and improve health outcomes. Sweetchs technology converts data points from smartphones and connected devices into personalized recommendations. The company believes in building continuous relationships between various stakeholders in healthcare to outsmart chronic conditions. Sweetch is HIPAA and GDPR compliant.
Investment
AI In Healthcare Use Case #30: Sweetch - Disruptor Daily
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $44.8M |
| Last funding | Undisclosed |
| Stage | A |
| Rounds | 8 |
| Investors | 15 |
Team Members
6
Employees: 51-200
Web & Social Links
| Website | www.sweetch.com |
| Google Play | Google Play |
Locations
Zeev Jabotinsky St 5, Ramat Gan, 5252006, Israel
Photos & Videos
2 item(s)
Sweetch Business
Business models
B2B2C
Product stage
Released
Employees
51-200
Sector
Health Tech & Life SciencesDigital HealthcarePatient EngagementTarget Customer
Healthcare & Life SciencesHealthcarePatientsProvidersLife SciencesPharmaceuticalsMedical Devices IndustryCore Technology
Platforms & InterfacesMobileArtificial IntelligenceMachine LearningTags (25)
clinical-trialspreventionmachine-learningpatientswellnessbehavior-analyticsdigital-healthcarepersonalizationnutritionchronic-diseaseactionable-insightsartificial-intelligencetelehealthhealthcare-providersdata-analyticspredictive-analyticsdigital-therapeuticsdisease-managementinsurtechrecommendationschronic-patientsmobile-applicationsmedical-device-manufacturerspatient-engagementpharma-companiesGeographic Markets
EuropeUnited StatesSouth AmericaCanadaNetherlandsSweetch Financials
$44.8M
Total funding
Undisclosed
Capital raised
Undisclosed
Last funding
A
Funding stage
8
Total rounds
15
Investors
Cumulative Funding Raised Over Time ($)
$1.3MApr 2015
$4.8MApr 2016
$12.8MApr 2024
$12.8MAug 2024
$14.3MFeb 2019
$34.3MJul 2021
$44.8MMay 2020
$44.8MMay 2025
Private Equity Funding
Undisclosed Round
May 2025
Undisclosed
VentureIsrael (Lead)
Undisclosed Round
Aug 2024
Undisclosed
tenmile (Lead)
SAFE
Apr 2024
$8M
OurCrowd, Tal Ventures
A Round
Jul 2021
$20M
Entrée Capital (Lead)
,
Noaber, Tal Ventures, Qure Ventures, OurCrowd, LIP Ventures, Philips, Kortex Ventures, OurCrowd, FinTLV Ventures
A Round
May 2020
$10.5M
Qure Ventures, OurCrowd
A Round
Feb 2019
$1.5M
Philips Ventures, OurCrowd
A Round
Apr 2016
$3.5M
OurCrowd, LionBird, Pontifax, Philips
Seed
Apr 2015
$1.3M
Pontifax, LionBird, SeedIL Ventures
Sweetch Lifecycle
Cumulative Funding Raised Over Time
$1.3MApr 2015
$4.8MApr 2016
$12.8MApr 2024
$12.8MAug 2024
$14.3MFeb 2019
$34.3MJul 2021
$44.8MMay 2020
$44.8MMay 2025
All Events
Undisclosed Round
May 2025
Undisclosed
VentureIsrael (Lead)
Undisclosed Round
Aug 2024
Undisclosed
tenmile (Lead)
SAFE
Apr 2024
$8M
OurCrowd, Tal Ventures
A Round
Jul 2021
$20M
Entrée Capital (Lead)
,
Noaber, Tal Ventures, Qure Ventures, OurCrowd, LIP Ventures, Philips, Kortex Ventures, OurCrowd, FinTLV Ventures
A Round
May 2020
$10.5M
Qure Ventures, OurCrowd
A Round
Feb 2019
$1.5M
Philips Ventures, OurCrowd
A Round
Apr 2016
$3.5M
OurCrowd, LionBird, Pontifax, Philips
Seed
Apr 2015
$1.3M
Pontifax, LionBird, SeedIL Ventures
Sweetch News
13 articles
growth-positive
Sweetch Strengthens Advisory Board with Appointment of Obesity Medicine Expert and Innovator, Dr. Fatima Cody Stanford
Dr. Fatima Cody Stanford, an obesity medicine physician-scientist, has joined Sweetch as an advisor. Sweetch is a digital therapeutics innovator and creator of a precision engagement platform for chronic conditions. Dr. Stanford will help Sweetch implement obesity management practices with her expertise. The prevalence of obesity and overweight is increasing worldwide, and Sweetch aims to decrease the health impact of obesity through its hyper-personalized engagement solutions. Dr. Stanfords addition to the advisory board is expected to improve patients lives globally.
Partners
growth-positive
Sweetch 2.0 Revolutionizes Patient Partnership in Managing Chronic Disease Management
Sweetch, a digital therapeutics innovator, has announced a platform update to help patients comply with their chronic condition management regimens. The platform combines AI and EI technology to provide hyper-personalized recommendations and engage patients in their health journey. The new version features a consumer-app style interface and allows patients to create and implement plans for participatory health. It also provides insight into how specific behaviors affect cardiometabolic health. Sweetch aims to improve adherence to treatment regimens and achieve better health outcomes. The company is being used by some of the worlds largest healthcare organizations.
Customers
growth-positive
Sweetch Enters Strategic Partnership with Grupo Fleury's Saúde iD to Tackle Brazil's Chronic Disease Prevalence Amidst COVID-19 Pandemic
Sweetch has announced a partnership with Grupo Fleury, one of Brazils leading healthcare providers. Fleury will implement Sweetch as part of its Saúde iD telemedicine services to improve healthcare outcomes for patients with chronic conditions. The partnership aims to reach millions of patients struggling to adhere to their prescribed health regimens and minimize healthcare costs. Sweetchs platform has been clinically proven to motivate long-lasting behavioral change and adherence. The initial deployment will focus on patients with obesity, pre-diabetes, and Type 2 diabetes, with plans to expand to other chronic health conditions. The integration of Sweetchs program in Fleurys divisions has already shown positive results, including increased physical activity and weight loss among users. Brazil has a high prevalence of chronic diseases, and Sweetch aims to address these underlying conditions to reduce the risk of COVID-19 complications. The partnership is part of Fleurys growth plan to build a Sweetch community of hundreds of thousands of users within three years.
Partners
growth-positive
Sweetch Secures $20 Million Series A to Accelerate Fully Automated Hyper-personalized Engagement Between Health Ecosystem Players and People with Chronic Conditions
Sweetch, a digital therapeutics innovator, has completed a $20 million Series A funding round. The funds will be used for global expansion and further development of their AI and emotional intelligence behavioral science technology. The funding round was led by Entrée Capital and joined by several other investors. Sweetchs platform is used for chronic disease management and has shown significant improvements in clinical outcomes. The company aims to provide a hyper-personalized solution to increase patient adherence and improve health outcomes. Sweetchs technology converts data points from smartphones and connected devices into personalized recommendations. The company believes in building continuous relationships between various stakeholders in healthcare to outsmart chronic conditions. Sweetch is HIPAA and GDPR compliant.
Investment
AI In Healthcare Use Case #30: Sweetch - Disruptor Daily
growth-positive
https://www.jpost.com/Opinion/Hillels-Tech-Corner-Getting-healthy-with-tech-593200?utm_campaign=ourcrowd%20weekly%20newsletter&utm_content=73948629&_hsenc=p2anqtz-9vx4xl1xnrbakfxsaelhflqp3-fc3vkzmrdnoqru6ogrlwyt_cocx-nbtmdhtmslhlnqtt_jg40d72k73rb-s4afdt6q&_hsmi=73948629
Sweetch Health, an Israel-based company, aims to leverage the mobile device to offer personalized digital health coaching. The company addresses chronic diseases and aims to improve patient adherence to treatment recommendations. Sweetch has raised $7.3 million in venture funding and offers a free mobile app for consumers. In a clinical trial conducted by Johns Hopkins, Sweetchs approach showed 86% user retention and improved health outcomes. The company is building partnerships with pharma companies, insurers, healthcare providers, and employers to fight epidemics.
CustomersInvestment
growth-positive
IQVIA, EMIS Health partner to support GPs in England electronically 'prescribe' apps to patients
Data science company IQVIA has partnered with EMIS Health to enable GPs in England to electronically prescribe apps to patients. IQVIA will help populate the EMIS App Library, bringing together their AppScript digital health prescribing and monitoring platform and the EMIS Web clinical system. The partnership aims to improve patient engagement and outcomes by having clinicians recommend and prescribe digital therapeutics apps. The collaboration is seen as a critical step in the maturation of digital health and breaking down silos between routine care and research.
Partners
growth-positive
Sweetch: Promising Patients' Compliance and Engagement with AI-based Behavioral Intelligence Engine
The article discusses the impact of AI in the healthcare industry, specifically in patient engagement and chronic disease management. Sweetch, a mobile-health platform utilizing AI, aims to increase patients compliance and adherence to health recommendations through its Behavioral Intelligence Engine. The platform provides personalized recommendations for healthier lifestyles and disease management. Sweetch has been clinically validated and has achieved positive results in clinical trials. The companys AI technology allows for flexibility and customization across different disease domains. Sweetchs B2B client base includes pharma companies, insurers, healthcare providers, and self-insured employers. The company focuses on continuous improvement of its AI algorithms, offers an outcome-based business model, and builds a unique data asset. The CEO emphasizes a people-focused approach and collaboration with industry leaders and healthcare institutes.
CustomersPartners
growth-positive
Israeli startup Sweetch leverages AI for diabetes prevention
Israeli company Sweetch, founded in 2013, offers an AI-based platform for identifying individuals at high risk of developing type 2 diabetes. The company aims to prevent diabetes by providing personalized recommendations and weight loss plans through its app and digital scale. Sweetch works with health providers, insurers, and pharma companies to bring its approach to their patient populations. A three-month clinical trial conducted at Johns Hopkins University showed positive results, with participants lowering their A1C levels, increasing physical activity, and losing weight. Sweetch previously raised $3.5 million in a Series A round led by OurCrowd and Philips and is now seeking another round of funding to scale up.
CustomersPartnersInvestment
growth-positive
U.S. Healthcare System WellSpan Partners with Mobile Health App Sweetch on Diabetes Treatment
Tel Aviv-based Sweetch Health Ltd. has partnered with Pennsylvania-based healthcare system WellSpan Health to develop an artificial-intelligence-based health and risk assessment app for chronic conditions. The app will be used to augment WellSpans diabetes treatment program and will be made available to WellSpans 15,000 employees, including primary care and specialty physicians. Sweetch previously raised $3.5 million from various investors.
Partners
growth-positive
Johns Hopkins Study Reveals Artificial Intelligence (AI)-Driven Mobile App Sweetch Reduces Blood Sugar Levels in Early Stage Diabetes Patients
Sweetch, a mobile-health app, has revealed the outcomes of its clinical trial conducted at Johns Hopkins University. The study shows that using Sweetch significantly lowered A1C levels, increased physical activity, and reduced weight for patients with early stage diabetes. Sweetchs machine-learning technology offers personalized recommendations to improve patient outcomes. The company raised $3.5 million in a Series A round led by Philips and OurCrowd. The clinical trial demonstrated significant behavior changes in participants, with high retention rates. Sweetchs technology enables large-scale intervention at a low cost. The study was led by Dr. Nestoras Mathioudakis at Johns Hopkins University.
Customers
growth-positive
Sweetch's AI-driven app claims to reduce risk of developing diabetes
Sweetch, a mobile health app that helps prevent diabetes and improve outcomes for people with diabetes, has revealed the outcomes of its clinical trial conducted at Johns Hopkins University. The study shows that using Sweetch significantly lowered A1C levels and increased physical activity for patients with early stage diabetes. Sweetch is a fully automated, AI-based personal digital intervention program that provides personalized recommendations to individuals. The company is focused on business development and marketing, seeking partnerships with self-insurers, health providers, and payers to reduce the long-term risk of diabetes. Sweetch raised $3.5 million in funding in 2016 led by Philips and OurCrowd.
CustomersPartnersInvestment
growth-positive
Israeli digital health startup to predict diabetes risk raises $3.5M
Sweetch, a startup focused on diabetes prevention, has raised $3.5 million in a Series A funding round led by OurCrowd and Philips. The companys app assesses individuals diabetes risk and guides them towards the key objectives of the Diabetes Prevention Program. Sweetch plans to enter the U.S. market and be prescribed by doctors there. The funding will support its expansion efforts. The companys chief medical officer is Dr. Yossi Bahagon, who previously led Luminox and worked with Johns Hopkins Technology Ventures. Dana Chanan is the CEO of Sweetch.
InvestmentExpand
Sweetch Team
Employee Info
| Employees (range) | 51-200 |
| Exact count | 59 |
| Team members | 6 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 14 classification IDs that could be used for matching.
Sweetch Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 100/100 |
| Missing | markets |
| BI Verification | Sharon Shapira |
| Registrar ID | 514984046 |
| Crunchbase | sweetch-2 |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2024-08-28T00:00:00.000Z |
| Created | 2014-11-17T00:00:00.000Z |
| Claimed | Yes |